The story so far
written Oct 26What is happening
AstraZeneca reported on October 26, 2026, that its experimental antibody-drug conjugate sonesitatug vedotin (Sone-Ve) doubled median overall survival to 10 months for patients with specific advanced gastric cancer 1. The CLARITY-Gastric01 Phase III trial, which included 532 participants, showed the drug reduced the risk of death by 42% compared to standard chemotherapy 1. The company is presenting data from this and three other pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress through October 27 67.
What to watch
A formal filing for regulatory approval with the FDA or EMA would follow these Phase III results. The company is currently presenting overall survival data for savolitinib in lung cancer and Imfinzi combinations in bladder cancer at the ESMO Congress 713. A formal approval decision from regulatory agencies for these filed treatments would establish their commercial availability. The announcement of a commercial launch or the abandonment of specific programs would conclude the current development cycle.
Read the full brief · how we got here
How we got here
The FDA granted accelerated approval to an AstraZeneca breast cancer treatment on September 4, 2026 12. On September 29, the company filed for U.S. approval of a lung cancer drug combination developed with Hutchmed 8. AstraZeneca also invested $2 billion in Summit Therapeutics through preferred shares as of September 28 to expand its oncology portfolio 5.
References · 7
- 1ndtv.com — AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Trial
- 5finance.yahoo.com — AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple?
- 6biopharmawatch.com — AstraZeneca Showcases Cancer Data at ESMO 2026 - AZN
- 7astrazeneca.com — AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys
- 8reuters.com — AstraZeneca files for US FDA approval of HUTCHMED ...
- 12fda.gov — FDA Grants Accelerated Approval to a New Breast Cancer Treatment | FDA
- 13astrazeneca-us.com — AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savoliti
What would close this
0 of 4 metTimeline
1newest firstWhen we started following: AstraZeneca stomach cancer drug doubles survival in Phase III trial, leading oncology expansion at ESMO 2026
AstraZeneca announced on October 26, 2026, that its investigational antibody-drug conjugate sonesitatug vedotin (Sone-Ve) doubled median overall survival to 10 months in the CLARITY-Gastric01 Phase III trial 1. The study, involving 532 patients with CLDN18.2-positive advanced gastric cancer, showed a 42% reduction in the risk of death compared to standard chemotherapy 1.
The company is presenting data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress (October 23–27), including the SAFFRON trial for savolitinib in MET-driven lung cancer and the VOLGA trial for Imfinzi combinations in bladder cancer 67. In other regulatory developments, the FDA granted accelerated approval to an AstraZeneca breast cancer treatment on September 4, 2026 12, and the company filed for U.S. approval of a lung cancer drug combination with Hutchmed on September 29 8. AstraZeneca also recently invested $2 billion in Summit Therapeutics through preferred shares as of September 28 5.